The fully linked HTML version of this article has now been published.
JCS ePress
online publication date 30 Mar 2004
doi: 10.1242/jcs.01042
Research Article
Role of PPAR
and EGFR signalling in the urothelial terminal differentiation programme
Claire L. Varley,
Jens Stahlschmidt,
Wen-Chun Lee,
Julie Holder,
Christine Diggle,
Peter J. Selby,
Ludwik K. Trejdosiewicz,
and
Jennifer Southgate*
* Author for correspondence (e-mail: js35{at}york.ac.uk)
Recently, considerable interest has focused on the ability of activated peroxisome proliferator-activated receptor 
(PPAR) to promote cytodifferentiation in adipocytes and some carcinoma cells; however, the role of PPAR in normal epithelial cytodifferentiation is unknown. Using uroplakin (UP) gene expression as a specific correlate of terminal urothelial cytodifferentiation, we investigated the differentiation-inducing effects of PPAR activation in normal human urothelial (NHU) cells grown as finite cell lines in monoculture. Two high-affinity activators of PPAR, troglitazone (TZ) and rosiglitazone (RZ) induced the expression of mRNA for UPII and UPIb and, to a lesser extent, UPIa. The specificity of the effect was shown by pretreating cells with a PPAR antagonist, GW9662, which attenuated the TZ-induced response in a dose-specific manner. The PPAR-mediated effect on UP gene expression was maximal when there was concurrent inhibition of autocrine-activated epidermal growth factor receptor (EGFR) signalling through either the phosphatidylinositol 3-kinase or extracellular signal-regulated kinase (ERK) pathways. The use of a specific EGFR tyrosine kinase inhibitor, PD153035, correlated with PPAR dephosphorylation and translocation to the nucleus, indicating a mechanism for regulating the balance between proliferation and differentiation. This is the first identification of specific factors involved in regulating differentiation-associated gene changes in urothelium and the first unambiguous evidence of a role for PPAR signalling in the terminal differentiation programme of a normal epithelium.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
F. Ondrey
Peroxisome Proliferator-Activated Receptor {gamma} Pathway Targeting in Carcinogenesis: Implications for Chemoprevention
Clin. Cancer Res.,
January 1, 2009;
15(1):
2 - 8.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. J. Chapman, G. Kelly, and M. A. Knowles
Genes Involved in Differentiation, Stem Cell Renewal, and Tumorigenesis Are Modulated in Telomerase-Immortalized Human Urothelial Cells
Mol. Cancer Res.,
July 1, 2008;
6(7):
1154 - 1168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. MacLaine, M. D. Wood, J. C. Holder, R. W. Rees, and J. Southgate
Sensitivity of Normal, Paramalignant, and Malignant Human Urothelial Cells to Inhibitors of the Epidermal Growth Factor Receptor Signaling Pathway
Mol. Cancer Res.,
January 1, 2008;
6(1):
53 - 63.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Van Vleet, M. R. White, T. P. Sanderson, S. M. Cohen, M. Cano, L. L. Arnold, C. R. Waites, B. E. Schilling, J. Mitroka, and M. A. Dominick
Subchronic Urinary Bladder Effects of Muraglitazar in Male Rats
Toxicol. Sci.,
March 1, 2007;
96(1):
58 - 71.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Burgermeister, D. Chuderland, T. Hanoch, M. Meyer, M. Liscovitch, and R. Seger
Interaction with MEK Causes Nuclear Export and Downregulation of Peroxisome Proliferator-Activated Receptor {gamma}
Mol. Cell. Biol.,
February 1, 2007;
27(3):
803 - 817.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Relic, V. Benoit, N. Franchimont, M.-J. Kaiser, J.-P. Hauzeur, P. Gillet, M.-P. Merville, V. Bours, and M. G. Malaise
Peroxisome Proliferator-activated Receptor-{gamma}1 Is Dephosphorylated and Degraded during BAY 11-7085-induced Synovial Fibroblast Apoptosis
J. Biol. Chem.,
August 11, 2006;
281(32):
22597 - 22604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T.-T. Sun
Altered phenotype of cultured urothelial and other stratified epithelial cells: implications for wound healing
Am J Physiol Renal Physiol,
July 1, 2006;
291(1):
F9 - F21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.A. Crallan, N.T. Georgopoulos, and J. Southgate
Experimental models of human bladder carcinogenesis
Carcinogenesis,
March 1, 2006;
27(3):
374 - 381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Cross, I. Eardley, H. J. Leese, and J. Southgate
A biomimetic tissue from cultured normal human urothelial cells: analysis of physiological function
Am J Physiol Renal Physiol,
August 1, 2005;
289(2):
F459 - F468.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Luna-Medina, M. Cortes-Canteli, M. Alonso, A. Santos, A. Martinez, and A. Perez-Castillo
Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor {gamma} Activation
J. Biol. Chem.,
June 3, 2005;
280(22):
21453 - 21462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Ohlsson, J. M. A. Moreira, P. Gromov, G. Sauter, and J. E. Celis
Loss of Expression of the Adipocyte-type Fatty Acid-binding Protein (A-FABP) Is Associated with Progression of Human Urothelial Carcinomas
Mol. Cell. Proteomics,
April 1, 2005;
4(4):
570 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Fuenzalida, M. C. Aguilera, D. G. Piderit, P. C. Ramos, D. Contador, V. Quinones, A. Rigotti, F. C. Bronfman, and M. Bronfman
Peroxisome Proliferator-activated Receptor {gamma} Is a Novel Target of the Nerve Growth Factor Signaling Pathway in PC12 Cells
J. Biol. Chem.,
March 11, 2005;
280(10):
9604 - 9609.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-T. Kong, F.-M. Deng, P. Hu, F.-X. Liang, G. Zhou, A. B. Auerbach, N. Genieser, P. K. Nelson, E. S. Robbins, E. Shapiro, et al.
Roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases
J. Cell Biol.,
December 20, 2004;
167(6):
1195 - 1204.
[Abstract]
[Full Text]
[PDF]
|
|
|
© The Company of Biologists Ltd 2004
